Cargando…
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
Sunitinib is a tyrosine kinase inhibitor (TKI) used in treatment of metastatic renal cell carcinoma (mRCC), gastrointestinal stromal tumors and pancreatic neuroendocrine tumors. One of the most common side effects related to sunitinib is hypothyroidism. Recent trials suggest correlation between the...
Autores principales: | Buda-Nowak, Anna, Kucharz, Jakub, Dumnicka, Paulina, Kuzniewski, Marek, Herman, Roman Maria, Zygulska, Aneta L., Kusnierz-Cabala, Beata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366170/ https://www.ncbi.nlm.nih.gov/pubmed/28343336 http://dx.doi.org/10.1007/s12032-017-0928-z |
Ejemplares similares
-
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
por: Kucharz, Jakub, et al.
Publicado: (2016) -
α(1)-Acid Glycoprotein and Dietary Intake in End-Stage Renal Disease Patients
por: Maraj, Małgorzata, et al.
Publicado: (2021) -
Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients
por: Żyłka, Agnieszka, et al.
Publicado: (2018) -
Potential Prognostic Markers of Acute Kidney Injury in the Early Phase of Acute Pancreatitis
por: Wajda, Justyna, et al.
Publicado: (2019) -
Sterile leukocyturia affects urine neutrophil gelatinase-associated lipocalin concentration in type 2 diabetic patients
por: Gala-Błądzińska, Agnieszka, et al.
Publicado: (2016)